Audit: QRS - Tantra for Health & Longevity

Audit conducted on 22/09/2026 19:52 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	94
Passed	84
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol, time-to-effect, benefit, risk, gate, monitoring and qualitative content traces to ER lines 145–219, 241–287, 305–333, 355–371, 404, 434–452.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“No established target; track direction against own 30-day baseline” (marker_4_target) carried verbatim from ER line 439.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Absolute contraindication for psychedelics/MDMA kept absolute; all avoid-populations kept in the stop gate.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gates draw only from ER Key Interactions & Contraindications; benefits/risks only from their own ER sections.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, citations, author names or NCT identifiers appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Neutral, evidence-weighted register matching the ER.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Monitoring targets are presented as ranges, not instructions.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person address anywhere in the sheet.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Domain terms (kriya, yoga nidra) are the intervention’s own names, not avoidable jargon.
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	12-week / 120-minute session protocol presented without hedging on effort.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Ejaculation-retention prostate trade-off and PSA marker surfaced, which matter specifically to this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not appear.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings, gate headings, tier labels and column headers match the template byte-for-byte.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variable spans present; marker_#/qualitative_item_# rows expanded as designed.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Structural diff against the template shows no change outside the content spans, metadata and title.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section drawn on by the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard clinical dose”, “Minimum effective dose”, “Best time of day” taken verbatim from ER lines 355, 357, 361.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Monitoring row labels match the ER biomarker table verbatim.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji characters in the file; the ER’s ⚠️ Conflicted markers were dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to headline-level items; no section carries ER prose or explanations.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” line 3, closing “—” line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:04" is quoted, which the colon requires.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: tantra_2026-0911-0009_Opus_ER.md
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: 26.9.22, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: 2026-0922-1937.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the actual file name.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Tantra for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 09/22/2026, from qrs_creation_date 2026-0922-1937.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header block is identical to the template apart from the two variable spans.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens “Tantra is a family of practices — … — used for calm, sleep and wellbeing.”
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Mirrors ER lines 474–478.
7.3	[at_a_glance] is no longer than 70 words	🟢	65 words.
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	“genuine but modest”, “no study has ever tested tantra”, and the three harm classes all appear in the ER Conclusion.
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “paced breathing”, “guided deep relaxation” used instead of technical names.
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	ER lines 305–333.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All seven “Populations who should avoid Tantra” bullets plus the absolute psychedelics/MDMA contraindication.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Eight <li> elements, lines 569–576.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	ER’s explanatory glosses (“advanced diabetic eye disease with fragile new vessels”) stripped; no dashes carry trailing clauses.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	180/110 mmHg, 21 mmHg, 12 months, 90 days, first trimester and six weeks postpartum all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses; thresholds are written out as “above”.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	Section is populated, as the ER names avoid-populations.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	ER lines 307–323.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All eight caution/monitor bullets present; the psychedelics/MDMA absolute contraindication correctly excluded here and placed in the stop gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eight <li> elements, lines 584–591.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Em-dash glosses (“— blood-pressure medicines”, “— a common antidepressant class”) and all Mitigation text stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every named drug/supplement list retained (amlodipine…, diazepam…, sertraline…, melatonin…, beetroot nitrate…).
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	Section is populated, as the ER names nine interactions.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	ER Therapeutic Protocol, lines 355–361.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Standard clinical dose, minimum effective dose, best time of day.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER provides ten protocol bullets; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated from ER lines 355, 357, 361.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Anxiety & cognition, sleep quality, cortisol & calm — the three clauses of ER line 404.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Anxiety (High) and sleep (High) precede cortisol/perceived stress (Low).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER names three distinct time-to-effect aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	8–12 weeks, 2–6 weeks and single session all match ER line 404.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	ER lines 145–219.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four populated, tiers matching the ER’s own grading.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item reduced to the ER benefit heading; no Magnitude data carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any benefits item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers contain items in the ER.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	ER lines 241–287.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four populated, tiers matching the ER’s own grading.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item reduced to the ER risk heading; prevalence and hazard-ratio data omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any risks item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers contain items in the ER.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	ER Monitoring Protocol & Defining Success, lines 434–443.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eight ER biomarker rows present, with Target and Why columns carried verbatim.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 757, condensed from ER line 432.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	ER lines 447–452.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers present as qualitative_item_1–6.

Issues 22/09/2026 19:52

Pass rate 100.00%. No issues found.

Issues 22/09/2026 19:50

1. 9.5 — Dose qualifier dropped from interaction: The ER bullet at line 319 names “high-dose omega-3” among the blood-pressure-lowering supplements; the QRS interaction item (line 590) lists plain “omega-3”, dropping the dose qualifier that determines whether the interaction applies, while keeping “high-dose caffeine” in the adjacent item.

Fixes 22/09/2026 19:50

1. 9.5 — Dose qualifier restored for omega-3: The blood-pressure-lowering supplements interaction item now reads “high-dose omega-3” instead of “omega-3”, matching the ER bullet and the “high-dose caffeine” qualifier kept in the adjacent item.

Issues 22/09/2026 19:43

1. 1.1 — Eight-week window over-extended: action_2_sub (line 470) reads “Mantra meditation (Kirtan Kriya) or a yoga nidra recording, over eight weeks.”; the ER (line 357) attaches the eight-week duration to Kirtan Kriya only, not to the yoga nidra recording.
2. 4.5 — Content exceeds one A4 page: The combined height of the at-a-glance lede, the eight two-line contraindication items, ten benefit entries, eight monitoring rows and six qualitative bullets overruns the single-page budget; the Contraindications gate and the “Low” benefits tier are the largest overruns.

Fixes 22/09/2026 19:43

1. 1.1 — Eight-week window scoped to Kirtan Kriya: action_2_sub changed from “Mantra meditation (Kirtan Kriya) or a yoga nidra recording, over eight weeks.” to “Mantra meditation (Kirtan Kriya) over eight weeks, or a daily yoga nidra recording.”, matching the ER’s attribution of the eight-week duration.
2. 4.5 — At-a-glance lede tightened: Trimmed the lede from 67 to 65 words (“chanting with mental imagery” → “chanting with imagery”; dropped the trailing “and” clause), reducing the 16px block by one rendered line.
3. 4.5 — Contraindications gate condensed: Shortened all eight items while keeping every threshold and window (180/110 mmHg, 12 months, first trimester / six weeks postpartum, 21 mmHg, 90 days) — e.g. “Personal or first-degree family history of a psychotic disorder, bipolar I disorder, or a dissociative disorder” → “…of psychotic, bipolar I or dissociative disorder”.
4. 4.5 — Key Interactions gate condensed: Trimmed two entries to single-line length (“Over-the-counter sedating antihistamines” → “Sedating antihistamines”; “beetroot nitrate, garlic extract, hibiscus, high-dose omega-3” → “beetroot nitrate, garlic, hibiscus, omega-3”).
5. 4.5 — Benefits and Risks entries tightened: Condensed the five-item “Low” benefits tier and the “Medium”, “Low” and “Speculative” risk tiers to bare noun phrases, saving roughly three rendered lines across both cards.
6. 4.5 — Protocol and Time-to-effect subs shortened: Compressed action_1_sub, action_3_sub, time_1_sub and time_3_sub to single short clauses (e.g. “Anxiety and cognitive changes were measured at 8–12 weeks in the trials.” → “Measured at 8–12 weeks in the trials.”).
7. 4.5 — Monitoring cadence and Qualitative Assessment trimmed: Shortened the cadence line (“at four weeks, twelve weeks, then every six months” → “at four and twelve weeks, then six-monthly”) and three qualitative bullets, including dropping the practice-log tail from item 6.